Table 1.
Demography and asthma characteristics at screening, full analysis population.
| Fluticasone/formoterol |
Fluticasone |
Fluticasone/salmeterol |
Total |
||
|---|---|---|---|---|---|
| (n = 167) | (n = 171) | (n = 168) | (n = 506) | ||
| Age (years) | Mean (SD) | 8.4 (1.81) | 8.4 (1.86) | 8.6 (1.80) | 8.5 (1.82) |
| Gender (n) | Male/female | 109/58 | 116/55 | 113/55 | 338/168 |
| Race [n (%)] | Caucasian | 164 (98.2) | 167 (97.7) | 165 (98.2) | 496 (98.0) |
| Asian | 3 (1.8) | 4 (2.3) | 3 (1.8) | 10 (2.0) | |
| Duration of asthma (years) | Mean (SD) | 3.5 (2.36) | 3.8 (2.50) | 3.5 (2.43) | 3.6 (2.43) |
| (n = 166) | (n = 167) | (n = 166) | (n = 499) | ||
| FEV1 presalbutamol (l) | Mean (SD) | 1.48 (0.361) | 1.44 (0.354) | 1.50 (0.360) | 1.47 (0.358) |
| % Predicted FEV1 | Mean (SD) | 73.8 (6.76) | 72.1 (7.17) | 73.5 (7.63) | 73.1 (7.22) |
| FEV1 reversibility (%) | Mean (SD) | 24.1 (10.49) | 26.1 (11.49) | 24.9 (9.75) | 25.0 (10.62) |
| Patients using ICS alone | n (%) | 118 (70.7) | 132 (77.2) | 129 (76.8) | 379 (74.9) |
| Median daily ICS dose | μg (min, max) | 200.0 (37.5, 500.0) | 200.0 (50.0, 500.0) | 200.0 (50.0, 500.0) | 200.0 (37.5, 500.0) |
| Patients using ICS and LABA | n (%) | 49 (29.3) | 39 (22.8) | 39 (23.2) | 127 (25.1) |
FEV1, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; SD, standard deviation.